News
Public · Published
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
Aclaris Therapeutics priced an offering of 7,785,714 common shares at $3.50 each and pre-funded warrants for 6,500,000 shares, expecting about $50.0 million in gross proceeds before fees, with closing expected October 28, 2026.
Published:
Updated:
What happened
Aclaris Therapeutics priced an offering of 7,785,714 common shares at $3.50 each and pre-funded warrants for 6,500,000 shares, expecting about $50.0 million in gross proceeds before fees, with closing expected October 28, 2026.
Confirmed
Global impact / market context
The offering brings in roughly $50.0 million of cash to fund Aclaris, a clinical-stage biopharmaceutical company, meaning it has no approved products yet. Selling new shares dilutes existing holders, but the cash supports research spending without relying only on borrowed money.
Analyst inference
Participation from TCGX, RA Capital Management, Invus and a large mutual fund signals specialist investors backed the deal. Pre-funded warrants let certain investors hold an economic stake before receiving shares, which can ease ownership reporting rules, while underwriters Leerink, Piper Sandler, Cantor and LifeSci managed the sale.
Analyst inference
What to watch
- Aclaris said the offering is expected to close on October 28, 2026, subject to customary closing conditions, so the cash is not yet final until those conditions are met. Confirmed
- Watch how Aclaris uses the roughly $50.0 million of gross proceeds, since the article does not specify spending plans for research, trials or general corporate purposes. Proposed
- Track the share count after closing: adding 7,785,714 shares plus 6,500,000 warrant-linked shares raises total shares outstanding, which lowers each existing holder's ownership percentage. Analyst inference